Resources
4 Results (showing 1 - 4)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 7/26/2023 (updated 3/28/2024)
This breakout session provided insights from project leaders on how to respectfully collaborate with Indigenous communities. Furthermore, we shared the ways that the Community Conversations approach empowers individuals across communities to participate in and to lead change; supports recovery; and lays a foundation for current and future generations to live healthier lives.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 1/26/2022 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) looked at data from six states mandated to report on neonatal abstinence syndrome (NAS), a condition that occurs when newborn babies experience withdrawal from drugs. A previous study of these states – Arizona, Florida, Georgia, Kentucky, Tennessee, and Virginia – indicated that the reporting helped determine the prevalence of NAS and identify communities more severely affected. The current report is based on answers to a follow-up questionnaire given to epidemiologists and birth defects program managers from the same six states.
Posted 9/1/2021 (updated 4/2/2024)